Anacor will receive a $7m upfront payment from Medicis and will be primarily responsible for discovering and conducting early development of product candidates which utilize Anacor’s proprietary boron chemistry platform.
Medicis will have an option to obtain an exclusive license for products covered by the agreement.
Anacor will be eligible for future research, development, regulatory and sales milestones of up to $153m, as well as high single-digit to low double-digit royalties on sales by Medicis.
Medicis will be responsible for further development and commercialization of the licensed products on a worldwide basis.